Darlene Dobkowski, MA

Even though wearable technology can track symptoms and physical activity, among other information, in patients with cancer, more research is needed to determine how it all can benefit the management of these patients by oncology nurses.

Amivantamab was approved by the FDA as first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations or as therapy for those whose disease progressed on or after platinum-based chemotherapy.

An expert discussed how the benefits of mindfulness in patients with cancer can also be applied to oncology nurses.

During a Community Case Forum, Tiffany Bostwick, P.A., discussed how immunotherapy for advanced endometrial cancer has contributed to improved results compared with the previous standard of care.

Two experts commented on ways oncology nurses can learn more about administering TIL therapy and how they can play a supportive role for patients receiving the treatment.

Wearable technology can track hand hygiene protocol adherence, making wards more aware of their hand washing and sanitizing rates on a weekly basis.

The FDA approved osimertinib for use with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer that harbor EGFR exon 19 deletions or exon 21 L858R mutations.

Lifileucel is the first TIL therapy approved by the FDA for a solid tumor, specifically previously treated unresectable or metastatic melanoma.

Tepotinib has received a traditional approval from the FDA for metastatic NSCLC with MET exon 14 skipping alterations, updating the previous accelerated approval from 2021.

Irinotecan liposome has been approved by the FDA for use with oxaliplatin, leucovorin, and fluorouracil to treat patients with metastatic pancreatic adenocarcinoma.

Virtual reality headsets can be used to reduce anxiety in patients with cancer undergoing treatment and as an educational tool for nurses learning how to have difficult conversations with patients.

A recent study found that a 2.5-mg dose of olanzapine was noninferior to the 10.0-mg dose to control nausea/vomiting in patients with solid tumors treated with chemotherapy and was able to reduce daytime drowsiness from the drug.

An expert discussed how approaching the stigma around lung cancer in an empathetic way may be the tool to help eliminate disparities around screening for the disease.

Darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer may lower hospitalization rates but marginally longer lengths of stay vs treatment with placebo, androgen deprivation therapy, and docetaxel.

An expert discussed how oncology nurses can help social workers seek available financial resources for patients by opening the conversation about any needs to be addressed.

Erdafitinib was approved for the treatment of adults with locally advanced or metastatic urothelial carcinoma, which amends a previously approved indication of the drug.

Speaking with patients with cancer about financial toxicity, including available resources to help them pay for treatment and other necessities, can become a collaborative effort within an institution.

Pembrolizumab plus chemoradiotherapy has been approved by the FDA for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.

After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.

One patient speaks about her myeloproliferative neoplasm symptoms and how nurses have helped her along the way—despite issues with staffing shortages and high nursing turnover rates.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation lowered relapse and progression rates in relapsed large B-cell lymphoma.

Overall, 65.9% of patients who received the combination of pelabresib and ruxolitinib demonstrated a 35% or greater reduction in spleen volume by week 24.

Remote patient monitoring following CAR T-cell therapy may reduce costs while allowing nurses to maintain a close eye on patient parameters, although more research is needed to refine the process of alerting virtual nurses of potential issues.

Tarlatamab induced a 40% objective response rate among patients with pretreated small cell lung cancer—including many patients who had already received 3 lines of therapy.

The FDA has approved encorafenib plus binimetinib to treat adults with metastatic non-small cell lung cancer with a BRAF V600E mutation.

Tetyana Furmanets, CRNP, MSN, discusses the tools she uses to help patients navigate myeloproliferative neoplasm symptom management.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Tisagenlecleucel evoked similar efficacy and a preferrable safety profile in children and adults with B-ALL being treated in a real-world analysis, compared with the clinical trial ELIANA.

Findings presented at the 2021 San Antonio Breast Cancer Symposium suggest that Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with breast cancer.

Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.